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Abstract 
Advanced scaffolds used in tissue regenerating applications should be designed 
to address clinically relevant complications such as surgical site infection associated 
surgical procedures. Recognizing that patient-specific scaffolds with local drug delivery 
capabilities are a promising approach, we combined 3D printing with traditional salt-
leaching techniques to prepare a new type of scaffold with purposely designed macro- 
and micro-porosity. The dual macro/micro porous scaffolds of medical-grade 
polycaprolactone (mPCL) were characterized for their porosity, surface area, 
mechanical properties and degradation. The use of these scaffolds for local prophylactic 
release of Cefazolin to inhibit S. aureus growth was investigated as an example of drug 
delivery with this versatile platform. The introduction of microporosity and increased 
surface area allowed for loading of the scaffold using a simple drop-loading method of 
this heat-labile antibiotic and resulted in significant improvement in its release for up to 
3 days. The Cefazolin released from scaffolds retained its bioactivity similar to that of 
fresh Cefazolin. There were no cytotoxic effects in vitro against 3T3 fibroblasts at 
Cefazolin concentration of up to 100 µg/ml and no apparent effects on blood clot 
formation on the scaffolds in vitro. This study therefore presents a novel type of 
scaffolds with dual macro- and micro-porosity manufactured by a versatile method of 
3D printing combined with salt-leaching. These scaffolds could be useful in tissue 
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regeneration applications where it is desirable to prevent complications using local 
deliver of drugs. 
 
Keywords: 3D printing, medical grade PCL; infection; antibiotic; prophylaxis; 
biodegradable polymer; elution. 
 
1. Introduction: 
Scaffold-based tissue engineering inherits a similar risk of surgical site infection 
as any other implant based treatment. The use of implanted foreign body in surgery has 
been shown to reduce the minimal infecting dose of S. aureus up to 1000 fold for 
formation of a permanent abscess [1]. In fact, implants are recognized as a major 
contributing factor to these infections because of the formation of bacterial biofilms, a 
self-secreted polysaccharide matrix which adheres to implant surfaces and protects the 
embedded bacteria from the immune system and systemically administered antibiotics 
[2]. Surface modification and local delivery of antimicrobial agents has been proposed 
as a promising approach in preventing biofilm formation [3-7]. 
Infections associated with implants occur at significant rates (e.g. 0.8%-1.2% for 
total hip/knee replacement [8], 5-15% for several breast implants [9, 10]). They 
represent a challenging problem and burden on healthcare systems in terms of 
morbidity, mortality and treatment costs across all surgical disciplines. The two 
commensal bacteria normally found on patient’s skin Staphylococcus aureus (S. aureus) 
and Staphylococcus epidermidis (S.epidermis) have been identified as key pathogens in 
many of these infections [8]. Surgical site prophylaxis is currently the standard 
approach for infection prevention with systemic antibiotic administration before and 
after surgery. However, this mode of administration leads to low local antibiotic 
concentrations in the desired tissue and side effects such as organ toxicity and altered 
host microbiome[11]. It may also promote the development of antibiotic resistance in 
commensal bacteria in the body, which can then themselves cause disease or spread 
their resistance via plasmid transmission [12].  
The use of locally delivered antibiotics for surgical site prophylaxis is a 
promising approach for scaffold-based tissue engineering applications. Traditional 
methods of mixing antibiotic powder with polymers before manufacturing the mixture 
into cement for implantation are simple but have major disadvantages when heat- or 
solvent labile antibiotics are used [13, 14].  A large number of commonly used 
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antibiotics including all of the Cephalosporin family, which are the mainstay of surgical 
site prophylaxis, have markedly reduced activity when exposed to heat [15].  The same 
analysis also applied to local scaffold-based delivery of other drugs and molecules such 
as DNA, growth factors or chemotherapy drugs. Therefore, it is clear that advanced 
scaffold technologies should have scaffold fabrication methods that are independent 
from the drug loading process and that the latter should be designed to allow for in-
theatre preparation. These criteria are important for the clinical translation of these 
scaffolds as they permit treatment personalized to specific patients and surgical 
scenarios. 
We hypothesized that a microporous architecture in a scaffold would increase its 
surface area and facilitate the incorporation and retention of drug from its solution 
through simple drop or soak loading methods. 3D printing and fused deposition 
modelling (FDM) techniques have emerged as powerful tools to create patient-specific 
scaffolds with macro-porous architectures and mechanical properties suitable for 
cellular infiltration, vascularization, tissue formation and remodelling. FDM is 
particularly versatile in terms of input materials and has been used to make scaffolds 
with local drug delivery capability by modifying the input materials [16]. For example, 
Hollander et. al made indomethacin-PCL feeding filament by thermal extrusion before 
printed by FDM to make T-shaped scaffolds for drug delivery application in intrauterine 
system [17] . Yet the main limitation of mixing the input materials with drugs is that the 
drugs have to go through the material and scaffold fabrication processes, which often 
involve elevated temperature and/or harsh chemicals, which can inactivate and/or 
degrade drugs/antibiotics. In this study, we thus focus on employing FDM technique to 
create scaffolds having intra-bar/strut microporosity which would allow for loading of 
heat/chemical sensitive drugs. However, introducing microporosity into these scaffolds 
been reported only by a limited number of research groups and for only certain specific 
materials [18, 19].  
Here, we used a simple concept of combining FDM with salt-leaching and 
developed a new type of 3D printed scaffold with dual micro-and macro-porosity that 
offers versatile drug loading and controlled release capabilities. We used 
polycaprolactone as a model polymer because of its proven applications in many FDA-
approved medical devices, and its low melting temperature (60oC) but the 
manufacturing method is designed as applicable to other thermoplastic materials to fit 
various applications. Cefazolin was selected as a model antibiotic because it is 
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commonly used for prophylaxis against S. aureus infection and is particularly sensitive 
to elevated heat and organic solvents making it unsuitable for commonly used 
techniques [20]. 
 
2. Materials and Methods: 
Scaffold Design & Manufacturing: Medical grade poly(ε-caprolactone) (mPCL; 
Mn =70 kDa, Mw =120 kDa, Polydispersity = 1.69, in pellet form; from Purasorb PC12 
Corbion, Purac) was used to 3D print scaffolds. In order to achieve microporosity, 
mPCL was dissolved in chloroform (Sigma Aldrich, St Louis) and mixed with 
phosphate buffered saline (PBS)  particles that had been ground from PBS tablets 
(Sigma Aldrich, St Louis), and sieved to size less than 75μm at a weight ratio of 5:4 
(PCL: PBS). The porogen-mPCL suspesion in chloroform was then solvent-casted to 
create composite porogen-mPCL films which were left in a fume hood to dry and stored 
in a desiccator (Figure 1). The porogen-mPCL composite films were used to 3D print 
constructs 50mm x 50mm x 2mm in a laydown pattern of 0/60/120° as reported 
elsewhere[21]. Briefly,  PCL-porogen films were heat up to 110oC for 30 mins and then 
screw-extruded through  a metal nozzle of gauge 2 (inner diameter of 0.33mm). The x-y 
movement of the motorized stage and z-movement of the nozzle was computer-
controlled to produce 3 dimensional scaffolds with bar diameter of 0.3 mm and bar 
distance of 1 mm. The scaffolds were then left in deionised water for 4 weeks to allow 
leaching of the porogen to produce macroporous scaffolds with microporous 
intrastrut/bar architecture (hereafter referred to as “microporous scaffold”). mPCL only 
was also used to make scaffolds with solid strut/bar (hereafter referred to as “solid 
scaffold”) as reference using the same manufacturing process. Both types of scaffolds 
were then treated with 1M NaOH for 30 minutes on an orbital shaker to improve their 
hydrophilicity. Polycaprolactone is a polyester which is hydrolyzed by strong base such 
as sodium hydroxide and this hydrolysis introduces carboxylic and hydroxyl groups to 
the surface therefore increases the hydrophilicity. A 5mm biopsy punch was used to 
produce scaffolds of 5mm diameter x 1.5mm-2mm thickness as samples for 
experiments. Samples were sterilized by ethanol followed by UV irradiation.  
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Figure 1. Schematic of fabrication process of PCL scaffolds using FDM and salt-
leaching techniques. 
 
After leaching of mPCL over 14 days, scaffolds were dissolved in chloroform to 10% 
(w/v) and the solution’s cloudiness was measured at 600nm using a spectrophotometer 
(Beckman Coulter Inc., California, US). The amounts of porogen residual were 
determined using the standard curve made from porogen mixture in PCL 1% solution in 
chloroform. 
 
Cefazolin Loading: Scaffolds were loaded with Cefazolin (Sigma-Aldrich, St Louis) via 
a “solution drop-loading” technique. Cefazolin was first dissolved in 67% ethanol to 
give solutions of 745ppm, 1340ppm and 3350ppm. In a biosafety cabinet, scaffolds 
were placed in a 96-well plate 16±0.3mg scaffold each well and 5μL droplet of solution 
was dropped onto each scaffold and let dry. This loading process was repeated 3 times 
with at least 30 minutes in between to give total loading doses of 11.17μg (Low Dose), 
20.1μg (Med Dose) and 50.25μg (High Dose) per scaffold. 
 
GelMA Coating: The scaffolds were dip-coated using 2% (w/v) gelatin methacrylate 
(GelMA) solution which was prepared as per a protocol published previously[22]. The 
GelMA adsorbed on the scaffolds was then chemically crosslinked by ammonium 
persulfate (APS) and  Tetramethylethylenediamine (TEMED; Thermo Fisher 
Scientific). An additional group (n=9) of each of the High Dose Solid and Microporous 
scaffolds were left uncoated for comparison. 
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SEM Imaging: The scaffolds were gold-sputter coated and examined using 
scanning electron microscopy (Zeiss Sigma VP Field Emission SEM) operating at 5-
10kV. X-ray microtomography (micro CT) imaging was conducted to characterize the 
scaffold microarchitecture. X-rays were generated by a GE-Phoenix xs 180nf micro-
focus X-ray source and radiographs captured on a 3000x3000 silicon flat panel detector. 
Xray tube settings were 80kV and 110microAmps and reconstruction undertaken using 
a helical cone-bean filtered backprojection method[23]. The voxel size of the images 
was 2.2m. 
 
Porosity: The porosity was first calculated from the scaffold’s dimensions, 
weight and PCL density. The total volume of a PCL cylindrical scaffold was calculated 
using the dimensions measured with Vernier callipers, and the volume of PCL was 
calculated from scaffold’s weight based on density of the mPCL (1.145g/cm3 as per 
supplier). The porosity was calculated as below and reported as mean ± s.e.m (n=4): 
 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦 =  
𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑣𝑜𝑙𝑢𝑚𝑒−𝑚𝑃𝐶𝐿 𝑣𝑜𝑙𝑢𝑚𝑒
𝑡𝑜𝑡𝑎𝑙 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑 𝑣𝑜𝑙𝑢𝑚𝑒
, in which: 
total scaffold volume =π x height x (diameter/2)2 
mPCL volume = scaffold weight/mPCL density. 
The porosity of the microporous scaffolds was also determined from micro CT 
data by segmentation and image analysis of the 2D tomographic images. Each voxel of 
the sample was assigned a phase based on the X-ray attenuation corresponding to each 
voxel in the image. The solid scaffold gives a strong bimodal distribution of 
attenuations associated with solid PCL and open porosity between the struts. The 
microporous scaffold has additional porosity inside the struts and bars.  
 
Surface Area: The specific surface areas of the mPCL and microporous-mPCL 
scaffolds were measured by a surface area and porosity analyser (Tristar II 3020 Surface 
Area Analyser, Micromeritics, Ottawa). Surface area was measured by performing N2-
adsorption–desorption experiments at 77 K. The samples were degassed at 150 °C 
under N2 flow overnight before analysis. Surface areas were calculated using Brunauer–
Emmet–Teller (B.E.T) model. 
Mechanical Testing: Scaffold’s compressive modulus was determined using Instron 
5567 (Instron, Massachusetts) uniaxial testing system with a 5kN load cell and 
maximum displacement of 15% (n=3). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
7 
 
Zeta Potential: A SurPASS electrokinetic analyzer (Anton Paar) was used for 
surface zeta potential measurements of scaffolds. In each zeta potential recording, two 
identical samples were attached to the adjustable gap cell to face each other with a 100 
µm gap between them. The streaming current was measured between two Ag/AgCl 
electrodes placed at both sides of the samples. The measurements were performed using 
1 × 10−3 m KCL solution as the electrolyte. The VisioLab interface calculated the zeta 
potential from the streaming current measurements according to the Fairbrother–Mastin 
approach (1) 
 (1) 
where dU/dp is the slope of the streaming current versus pressure, η is the viscosity of 
the electrolyte, ε is the dielectric constant of the electrolyte, ε0 is the vacuum 
permittivity and KB is the specific electrical conductivity of the electrolyte solution 
outside the capillary system. 
 
Accelerated degradation: PCL is a polyester of slow hydrolysis-based 
degradation rate; therefore we compared degradation properties of the PCL scaffolds 
using accelerated degradation in NaOH (Figure 2). Samples were placed in NaOH 2M 
solution and incubated at 37oC in shaking incubator at 200 rpm. The samples were 
recovered, washed with miliQ water and dried in vacuum until stable weights. The 
molecular weight of samples was determined by gel permeation chromatography 
(GPC). 
 
Gel permeation chromatography: GPC was used to study the change in 
molecular weight of PCL scaffolds after degradation in NaOH solution. Samples were 
dissolved in Chloroform with a concentration of 0.5% w/v and the solutions were 
filtered with a 0.22um filter. The molecular weights of samples were measured by 
Waters 1515 Isocratic HPLC Pump (Waters, Milford, MA) equipped with Waters 2487 
Dual Absorbance detector. Chloroform was used as a mobile phase at a flow rate of 
1mL/min. 10uL of sample was injected for each measurement and the measurement was 
run for 40 minutes. 
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Figure 2. Schematic of accelerated degradation experiment. 
Cefazolin release from scaffold: Release of Cefazolin from scaffolds was tested 
in sterile PBS with the PBS volume/scaffold weight ratio of 10μL/mg in a shaker 
incubator set at 37°C and 225 RPM.  The eluate was collected and replaced with fresh 
sterile PBS every hour for the first 6 hours and then every day for 7 days. The 
concentration of the Cefazolin in eluate was determined by measuring  absorbance at 
272nm using a spectrophotometer (x-Mark, BioRad, California) and a standard curve of 
known Cefazolin concentrations.  
 
Biocompatibility Testing: Cytotoxicity was tested using murine embryonic 3T3 
fibroblasts (CCL-92, ATCC, VA, USA) and AlamarBlue assay. A standard curve was 
first created by culturing cells to 70-80% confluence in complete Modified Eagle 
Medium (αMEM, Thermo Fischer Scientific) which was supplemented with 10% v/v 
fetal bovine serum (FBS, Sigma-Aldrich) and 1% penicillin–streptomycin (PS, Sigma-
Aldrich), cells were seeded in wells of a 96 well plate with decreasing density in 100uL 
complete αMEM. The plates were incubated at 37°C for 12 hours, then the culture 
medium removed and 100uL of 10% Alamarblue in complete αMEM was added for a 
further 4 hour incubation after which 50uL from each well was transferred to a black 
96-well plate and fluorescence intensity was measured using a plate reader (Polarstar 
Optima, BMG Labtech, Ortenberg) with excitation of 544nm and emission of 590nm.  
For Cefazolin cytotoxicity testing, the cells were seeded in a 96-well plate at a density 
of 104 cells in 100uL complete αMEM and cultured for 24 hours at 37°C, culture media 
was removed and replaced with serially diluted solutions of Cefazolin in complete 
αMEM . The plate was incubated for 24 hours at 37°C, then medium removed and 
100uL 10% Alamarblue in αMEM added, after a further 4 hours incubation the 
fluorescence intensity of the solution was measured as above.  Cells treated with 100% 
Phenol and culture media only serve as positive and negative controls. Experiments 
were repeated 3 times with n=3 replicates in each repeat (n=3). 
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Antibiotic Bioactivity Testing: S. aureus (ATCC29213) was used for the 
experiments. Growth of the bacteria was first characterized. Bacteria colonies were 
selected from agar plates and inoculated into 10ml Lysogeny Broth (LB) and incubated 
for 12-16 hours on a shaker incubator set at 37°C and 225 RPM. The  absorbance at 
600nm (OD600) of 100μL bacterial suspension was measured and correlated to the 
number of colony forming units (CFU) determined by the agar plate spreading and 
counting method. From the overnight culture, bacteria were diluted to 5x108 CFU/mL in 
LB and incubated in a shaker incubator at 37°C 225 RPM and the OD600 and CFU 
counts were determined every hour for 6 hours to characterize the early log phase 
bacterial growth. The late log phase growth of bacteria was characterised by diluting in 
1:1 double strength cation-adjusted Muller-Hinton Broth (2xCAMHB, with 40mg/l of 
CaCl2 and 20mg/l of MgCl2) and PBS, and plating in a 96-well plate to give 100uL of 
5x106 CFU/ml per well, the plate was then incubated at 35°C statically and the OD600 
measured and CFU counted by plating method every hour for 8 hours.   
The minimum inhibitory concentration (MIC) of fresh Cefazolin to kill 50% and 
90% (MIC50 and MIC90) of late log phase S. aureus was determined by adding 5x105 
CFU bacteria into each well of a 96 well plate followed by adding serially diluted 
Cefazolin solutions and cultured for 12-16 hours 35°C statically. PBS solution was used 
as a negative control. Testing the bioactivity of the Cefazolin in the eluates released 
from scaffolds was carried out using this protocol by diluting eluates in double strength 
CAMHB containing 5x105 CFU bacteria and incubating for 8h in a shaker incubator at 
35°C, 225 RPM. The absorbance at 600nm (OD 600) was then measured and the 
CFU/ml was calculated from the pre-established standard curve and normalized by that 
of PBS only negative control. 
 
Agar diffusion testing: S. aureus was plated on Mueller-Hinton agar, and 
scaffolds (square, 2mmx2mmx 1.5mm) loaded with Low Dose, Medium and High 
doses of Cefazolin were placed and gently pressed to have stable contact with agar to 
allow for diffusion of drug into the agar. The plates were incubated at 37oC for 12 hours 
and zones of inhibition were measured with a ruler. 
 
Blood Clot Formation: Sheep whole blood was freshly collected into Vacuette® 
tube (Greiner Bio-one, Kremsmünster) 3.5mL 9NC coagulation sodium citrate 3.2% 
and stored at 4oC. Blood and CaCl2 0.2M were warmed to 37
oC for 1 hour prior to 
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experiments. 190µL blood was added into each 2mL Eppendorf tube and a scaffold of 
known weight was added to the tube. Then 10µL of CaCl2 0.2M was added to each tube 
and gently mixed. The tubes were incubated for 2 hours. Finally the clots were gently 
collected from the tubes and weighed. Solid scaffolds and microporous scaffolds loaded 
with High Dose Cefazolin was compared to a control group of no scaffolds (n=5). 
  
Statistical Analysis: Data were reported as mean ± SEM unless otherwise 
indicated, and statistical significance between groups were determined by two-tailed 
students t test. 
 
3. Results: 
3.1. Scaffold manufacturing and characterization 
The SEM images were taken at 3 magnifications to show the morphology of 
PCL scaffolds, the cross sections and surfaces of the struts and bars. SEM imaging 
showed clear presence of pores in micrometre scale within the microporous scaffold 
struts (Figure 3a,c) as the result of the salt-leaching process compared to solid struts of 
the normal mPCL scaffolds (Figure 3b,d). 
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Figure 3. Scaffold characterization. Overview images (insets) and SEM images of 
scaffolds at increasing magnifications for microporous scaffolds ((a1)-(a3)), normal 
scaffolds (solid strut, (b1)-(b3)) and GelMA coated microporous scaffolds ((c1)-(c3)) 
and GelMA coated solid scaffolds ((d1)-(d3)). Scale bars = 500 μm for (a1)-(d1); 200 
μm for (a2)-(d2); 50 μm for (a3)-(d3). Micro CT images of e) microporous scaffold and 
f) solid scaffold at two representative cross sectional planes. Microporosity analyzed by 
measuring in 2D slice images from micro CT is c.a. 41%. Circular non-interconnected 
pore present in the solid scaffolds (f) are believed to result from air entrapment during 
the extrusion process. g) The leaching process of mPCL over 14 days indicating 
complete leaching of porogen was achieved. Scaffolds were dissolved in chloroform to 
make solutions of 10 %( w/v). Any porogen remained in the scaffold would give rise to 
the solution absorbance which was measured with a spectrophotometer. 
 
The majority of micropores have relatively similar sizes ranging from c.a. 20μm 
to c.a. 70μm with few particularly larger pores which were likely the result of porogen 
aggregation during the sample making processes. Microporosity was further 
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characterized using micro-CT which interestingly showed occasional spherical pores in 
the solid  scaffolds (Figure 3e, f). The presence of these spherical pores in the struts and 
bars of the solid 3D scaffolds was previously documented by our group and is likely the 
result of air bubbles entrapped during the melt-extrusion process, they are sparse and 
not interconnected. GelMA coating is visible as only a thin material at the edge of the 
struts, most noticeable where the struts fuse (Figure 3c, d). The leaching process 
demonstrated the progression of the removal of porogen during immersion and was 
complete after14 days (Figure 3 g). This conclusion is also supported by examination of 
the cross sections of 14 days leached scaffolds with SEM and micro CT showing the 
absence of porogen particles (Figures 3 a1 and e) 
 
The surfaces of microporous mPCL and mPCL scaffolds were found similar in 
terms of microscospic morphology, roughness (Figures 4a-b). The surface charges of 
these scaffolds were also not different (Figure 4g). The measured similar contact angles 
(Figure 4c) were therefore expected. 
The overall porosity (i.e., the total of microporosity and macroporosity) of the 
microporous scaffolds calculated using mPCL density and scaffold dimensions was 
80±1% compared to 62±0.3% for the solid scaffolds (Figure 4d). Since the two types of 
scaffolds were made using the same parameters of the 3D printing process, they were 
assumed to have the same macroporosity, the microporosity within the scaffold struts in 
the microporous scaffold was then calculated to be approximately 47%. This is in good 
agreement with the total microporosity of 41±11% obtained from analysis of microCT 
images. 
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Figure 4. Physicochemical characterization of microporous mPCL scaffolds compared 
to mPCL scaffolds showing mean + SEM for: a)& b) AFM imaging and surface 
roughness analysis showing non-significant difference in topography; c) contact angles 
demonstrating similar hydrophilicity as expected from surface hydrolysis of mPCL 
during leaching d) porosity determined using scaffold dimensions, weight and mPCL 
density (n=4). Total porosity was significantly higher for microporous scaffolds at 
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80±1% compared to 62±0.3% for the solid scaffolds. e) surface areas measured with gas 
adsorption and analyzed with B.E.T method was also significantly higher for the 
microporous group (data is average of 2 measurements) and f) compressive modulus 
(MPa) over three compressing - relax cycles (n=3) showing non-significantly lower 
values for microporous scaffolds. g) Mean Zeta potential for solid and microporous 
scaffolds showing both having negative surface charges with no significant difference 
as expected from the same post-printing treatment procedure to both scaffolds. (* p < 
0.05). 
 
 Surface Area: The specific surface area of the microporous scaffolds was also 
significantly higher for the microporous scaffolds at 4887±88 cm2/g compared to 
1260±76 cm2/g of the solid scaffolds (Figure 4e). 
 
Mechanical Testing: The microporous scaffolds showed lower (non-significant) 
compressive modulus compared to the solid mPCL scaffolds with the largest difference 
for the first cycle of compression-relaxing experiment (Figure 4f). This is expected as 
the intra-strut micropores would make the microporous scaffolds softer which could be 
beneficial for applications such as in soft tissue regeneration where it is desirable to 
have scaffolds mechanically similar to the native soft tissue. 
 
3.2. Degradation test. 
The accelerated degradation test demonstrated increased porosity in 
microporous scaffolds evident on scanning electron miroscope imaging around the 
perimeter and centrally within the struts (Figures 5b1-b2, d1-d2). The molecular weight 
increased for the solid mPCL is attributed to the removal of amorphous/less crystalline 
regions of the polymer in the first steps during degradation. In contrast, a decrease in 
Mw was seen for for the microporous mPCL and this is attributed to the fact that the 
increased surface areas and porosity accelerated the degradation and has led to bulk 
erosion in the case of these scaffolds (Figure 5e). This conclusion is supported by the 
stark difference in morphologies of mPCL and microporous mPCL scaffolds both on 
the surface and in the cross sections in the SEM images (Figure 5 a1-d2) 
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Figure 5. Accelerated degradation test. mPCL and microporous mPCL scaffolds were 
immersed in NaOH 2M in a shaker incubator (at 37oC, 121 rpm) for 48 hours. SEM 
imaging revealed the substantial increase in porosity both on the surface and cross 
section of the microporous scaffold (scale bars = 100 μm). (e): GPC analysis showed 
results of molecular weight changes after the test; mPCL scaffolds exhibited slight 
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increase in Mw likely due to the removal of amorphous/less crystalline region during 
the degradation from the scaffolds. The reduction in Mw of microporous scaffolds is 
attributed to the bulk erosion as seen in SEM images on the surface and cross section of 
the scaffolds. 
Weight loss measurement showed negilible reduction for mPCL scaffolds and 
almost linear reduction of c.a. 65% in 48 hours in NaOH 2M.  
This degradation data indicated that the microporous scaffolds facilated the 
degradation of PCL which is preferable in many regenerative applications such as for 
soft tissue where the current slow rate (~ upto 2 years for complete degradation) is a 
limitation for PCL. 
 
3.3. Loading and release of antibiotics and its bioactivity. 
Cefazolin release: Both types of scaffolds showed capability to load and 
subsequently release Cefazolin. Microporous scaffolds demonstrated a clear dose-
dependent release characteristics while solid scaffolds showed no significant difference 
between the Medium Dose and High Dose in most of the time points tested which is 
likely due to a smaller surface area compared to microporous mPCL scaffodls (Figure 
6[A]).  
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Figure 6. Characterization of Cefazolin release kinetics from scaffolds. [A]: comparison 
of Cefazolin non-cumulative release profiles for GelMA coated microporous mPCL and 
solid mPCL over the first 6 hours and next 7 days reported as mean+SEM  (n=9)  a) The 
released Cefazolin concentrations showed dose dependence in both normal and 
microporous scaffolds. The microporous scaffolds also showed consistently higher 
release up to day 6 (comparing within the same dose group). b) The total Cefazolin 
amount released at each time point (in μg) was consistently higher for microporous 
compared to normal scaffolds for 3 consecutive days. [B]. Comparison of Cefazolin 
release profiles in PBS for microporous mPCL scaffolds with and without GelMA 
coating (n=9) at high loading dose a) total release from scaffolds with a reduced burst 
release for GelMA coated scaffolds which released significantly less in the first 6 hours 
and b) release at each time point presented as percentage of total released, with the 
GelMA coated scaffolds showing a more gradual release indicating a reduced burst 
release.  
 
The Cefazolin concentration the eluates from Cefazolin-loaded microporous 
scaffolds ranged from a mean of c.a. 25ppm in the first hour for the High Dose group to 
0.25ppm at day 7 for the Low Dose group (Figure 6[A]-a). The High Dose microporous 
scaffolds produced a concentration above the MIC90 for 4 consecutive days. The 
microporous scaffolds also released significantly more drug than the solid scaffolds for 
3 days (Figure 6[A]-b). The mean release per scaffold increased with loading 
concentration at the time points tested. The porous scaffolds demonstrated an initial 
‘burst release’ in the first few hours followed by a sustained release over 7 days. 
Importantly, the microporous scaffolds with GelMA-coating exhibited a lower burst 
release (Figure 6[B]-a)(i.e., release in the first 6 hours) compared to scaffolds without 
GelMA coating.  
 
Loading efficacy: Loading efficacy was calculated  as the ratio of total amount 
released to the original drop-loaded Cefazolin amount. The loading efficacy was 
significantly higher for the GelMA coated microporous scaffolds at 4.10.2, 5.60.5, 
7.00.4% for High Dose, Med Dose and Low Dose respectively compared to 1.50.1, 
4.20.3 and 5.50.5% for the solid scaffolds. The High Dose uncoated scaffolds 
showed higher loading efficacy of 7.41.7% and 17.61% for solid and microporous 
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respectively but this was mostly seen as a burst release in the first hours with reduced 
subsequent release. 
 
Bioactivity Testing: The S. aureus strain showed typical initial lag phase followed by 
logarithmic early and late growth phase (Figure 7[A]-a) which would typically be 
followed by a stationary phase however this was not tested in our study. Testing using 
fresh Cefazolin solution showed an MIC90 of c.a. 0.8ppm and an MIC50 of c.a. 0.1ppm 
(Figure 7[A]-b).  Bioactivity of Cefazolin eluates collected at different time points from 
microporous mPCL scaffolds loaded with Low Dose, Medium Dose and High Dose 
demonstrated dose-dependent antimicrobial activity (Figure 7[B]) from which MIC90 of 
eluted Cefazolin was calculated to be approximately from 0.7 to 1.3 ppm, and an MIC50 
of c.a. 0.3ppm which is similar to that of fresh Cefazolin (Figure 7[A]-b). The 
antimicrobial activity of the microporous scaffold loaded with Cefazolin was also 
demonstrated through the zone of inhibition experiment [Figure 8c) which showed a 
dose-dependent zone of inhibition on the loading doses. 
 
 
Figure 7.  Antimicrobial activity of Cefazolin on S. aureus. [A] Effects of Cefazolin on 
planktonic S. aureus growth. a) Characterization of S. aureus growth demonstrating a 
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typical growth curve of the bacteria including an initial lag phase (3 hours) followed by 
log growth phase (8 hours) (n=3). The stationary phase was not tested in this 
experiment. Bacteria in the log growth phase were then used for subsequent antibiotic 
testing experiments. b) Growth curves of S. aureus treated with increasing 
concentrations of Cefazolin, demonstrating the MIC50 = 0.1 ppm and MIC90=0.8 ppm 
where 50% and 80% of bacterial growth was inhibited respectively (n=3)[14].       
[B] Bioactivity of Cefazolin eluates collected at different time points from microporous 
mPCL scaffolds loaded with Low, Medium   and High Dose of Cefazolin determined as 
CFU normalized by that of untreated control. Data = mean ± SEM (N=3 repeats with 3 
replicates in each repeat). The eluates demonstrated dose-dependent antimicrobial 
activity  from which MIC90 of eluted Cefazolin was calculated to be c.a 0.7 to 1.3 ppm, 
and an MIC50 of c.a. 0.3ppm which are similar to those of fresh Cefazolin in [A]b). 
 
3.4. Biocompatibility testing 
Metabolic activity (shown to correlate well with cell number Figure 8a) assays 
showed slight increase in cells treated with low Cefazolin concentration (< 1ppm) and 
remained high for concentrations up to 100ppm (Figure 8b). This is in agreement with 
other studies which show limited toxicity of Cefazolin below 100ppm[24]. 
ormation of a stable blood clot in macroporous scaffolds after implantation has 
been recognized recently by several groups as important for subsequent cellular 
infiltration and vascularization [25, 26]. Here we observed no detrimental effects of 
microporousity and Cefazolin loading on this process as indicated by similar clot 
weights (Figure 8d).  
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Figure 8: In vitro testing of biocompatibility and activity. Alamarblue assay on 3T3 
fibroblast cells. a) Standard curve correlating fluorescence intensity (excitation: 544nm, 
emission: 590nm) and fibroblast cell number (data = mean± SEM, n=3) showing strong 
correlation (R2=0.999). b) Fibroblast cell number (data = mean± SEM, N=3) after 24 
hour treatment with different concentrations of Cefazolin indicating no cytotoxicity of 
Cefazolin concentration of up to 100ppm. c) Agar diffusion test of Cefazolin-loaded 
microporous scaffolds (without GelMA coating) showing dose-dependent zone of 
inhibition on S. aureus. * p<0.05, data = mean ± S.E.M (n= 8). d) In vitro blood clot 
formation on scaffolds. No significant difference in blood clot weight formed in 
presence of microporous PCL scaffold without (PCL scaffold) and with high dose of 
Cefazolin (PCL Scaffold with Cefazolin) compared to control group without scaffold 
(blood only) (n=5).  
 
4. Discussion: 
It is being recognized that tissue engineering scaffolds should be designed to 
have multiple functions to (i) faciliate cellular attachement, infiltration and 
vascularization and also (ii) prevent complications such as infection to ensure succeful 
treatment outcomes [27, 28]. Criterion (i) has been realized by using scaffold surface 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
22 
treatment and scaffold’s macro-porosity with interconnected pores of around 300µ or 
above which is known to be crucial in vascularization of implanted scaffolds in 
regeneration of clinically relevant volumne of tissue [29]. Solid-free form fabrication 
techniques such as fused deposition modelling (FDM) are emerging techniques that 
allow for generation of patient- specifically shaped constructs with such properties [30]. 
Criterion (ii) has been often realized using drug-delivery approach where drugs (such as 
antibiotics, chemotherapeutics) are incorporated into the raw materials during the 
scaffold preparation [31, 32]. Yet, major limitations of this method include instability 
issue of the drugs and lack of control on specificity in dosing. 
 
This study aimed to develop a vesatile scaffold platform to enable loading of 
drugs indepently from scaffold fabrication process. A traditional porogen leaching 
technique was combined with FDM to produce polymeric scaffolds with a macroporous 
struts/bars structure that have intra-strut/bar microporosity. The introduction of 
microporosity in macroporous polycaprolactone scaffolds allowed for rapid and specific 
loading of model drug Cefazolin and its efficient release in a dose dependent manner. 
This study therefore demonstrated the proof-of-principle that drugs such as antibiotics 
could be readily loaded to scaffolds using simple solution-based, in-operation-theather-
ready loading method, and its release could be controlled and tailored for different 
applications in surgical site infection prophylaxis.  
A number of factors have been recognized to control the loading and release 
kinetics of water soluble drugs such as Cefazolin from carrier devices [33-35]. In this 
study, the loading of microporous scaffolds was correlated with increased surface area,  
hydrostatic forces and surface etching with NaOH. The microporous intrastrut/bar 
architecture was shown to increase the release efficacy with significantly more 
Cefazolin released for 3 days, and a greater overall total release. This is clinically 
relevant in the context of inhibiting the growth of bacteria introduced at surgery for 
tissue engineering applications where there are often constraints such as on scaffold 
weight and volume. These results also suggest that the drug release profile could be 
further controlled by varying the microporosity and/or pore size through porogen 
concentration and size during scaffold manufacturing. 
The use of a GelMA barrier coating was shown to dampen the initial burst 
release, which is recognized as undesirable in many cases because of the potential local 
toxicity and/or subsequent release of sub-therapeutic antibiotic levels. The combination 
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of microporosity and GelMA coating showed a smaller initial burst release over a few 
hours followed by an extended release over the next few days. This release profile is 
highly desirable for an antibiotic eluting device so as to target the risk of infection 
during initial inoculation and continue to prevent latent infection [34].  The use of the 
GelMA is analogous to the barrier coating on a reservoir type drug eluting devices. 
These systems often include a drug-containing polymer core and a drug free top layer 
that acts as a rate-limiting barrier leading to sustained drug release [36]. A small initial 
burst release can also be observed in these systems due to the migration of the drug into 
the top layer after preparation [33]. In this study, GelMA was chosen because of its 
versatility in production and biological properties; it has been shown to encourage 
cellular adhesion and proliferation and it can be readily photon – or chemically cross-
linked[37]. 
The released Cefazolin showed high retention of bioactivity which highlights an 
important advantage over traditional systemic administration of sustained local delivery 
systems where drug degradation in aqueous solution is greatly reduced[38]. In our 
experiments, there was only slight decrease in MIC50 and MIC90 of  Cefazolin released 
from scaffolds indicating that the scaffold-bound Cefazolin retained its bioactivity even 
when the scaffolds were immersed in PBS. Another important advantage of scaffold-
based local delivery is that peak concentration of Cefazolin around the scaffold is 
obtained immediately after implantation, which would be effective in targeting bacteria 
inoculated during surgery. Reports in the literature show that after systemic 
administration it takes up to 2 hours for tissue concentration of Cefazolin to reach peak 
and the pharmacokinetics of single dose resulted in peak tissue concentrations of up to 
24ppm with a half life of only 3 hours resulting in concentrations dropping below the 
MIC for S. aureus in under 24 hours [39].  
There are few reports in the literature focusing on local delivery of water soluble 
drugs such as Cefazolin from polycaprolactone vehicles. One such study used PCL 
incorporating foam pads made by freeze drying a solution of PCL and Cefazolin applied 
at the interface of a metal pin to prevent infection in a rabbit tibia model [40]. This 
report showed strong in vitro release of Cefazolin in the first day followed by more 
gradual release in days 2 and 3 and negligible release afterward. The application of a 
Cefazolin-loaded pad in the rabbit reduced the rate of S. aureus detection in the surgical 
wound. This Cefazolin-PCL foam is potentially useful but this method of incorporating 
Cefazolin has several limitations including limited solubility, potential degradation of 
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Cefazolin in the solvent and no system for achieving exact doses for specific scaffolds. 
The method of blending/mixing PCL with a drug is perhaps the most common approach 
reported in the literature to make drug delivery systems (scaffolds, meshes, membranes 
etc.). Teo et al. blended Gentamicin sulphate with PCL and tricalcium phosphate (TCP) 
and extruded the mixture to create mesh capable of local delivery of gentamicin to 
prevent wound infection [41]. However, the elevated temperature used in such thermal 
blending process has the potential to cause significant drug degradation. Another group 
3D printed PCL/PLGA scaffolds loaded with tobramycin and demonstrated bectericidal 
activity against S.aureus in vitro and successful treatment of established bone infection 
in a rat model[13]. This experiment was aimed at treating infection and used 
Tobramycin a known heat stable antibiotic, however this antibiotic is not appropriate for 
prophylactic use and there are no antibiotics commonly used to prevent infection which 
are heat stable[15]. Cryomilling could also be used for blending but it is an energy-
intensive and lengthy process, and obtaining the exact drug dosing for specific scaffolds 
is still challenging. Here we developed a new strategy to independently control the 
scaffold manufacturing and drug loading processes. Our novel scaffolds with 
micropores and increased surface area offer a versatile platform for drug incorporation 
using a simple solution soak/drop loading method and allow for specific dosing to suit 
different needs. 
Both the microporous scaffolds with and without Cefazolin showed no apparent 
adverse effects on blood clot formation. The formation of a haematoma after the 
surgical implantation of a tissue engineering scaffold and establishment of a blot clot 
are recognized as essential for cellular recruitment and the regeneration process in tissue 
engineering [42]. The stabilised clot acts as a supporting matrix for cell migration, 
provides growth factors and pre-cursor cells and facilitates the formation of a vascular 
network [42]. It is therefore imperative that a tissue engineering construct does not 
impede blood clot formation as was demonstrated with these scaffolds. 
A limitation in our experimental procedure was the fact that our methods of 
drop-loading of antibiotic onto scaffolds and dip coating with GelMA has not been 
optimized, which is believed to have resulted in low overall loading efficacy (less than 
10%). This drop-loading method was used so as to devise an in-theatre-preparation 
method which would allow Cefazolin to be loaded onto previously prepared 
microporous scaffold with specific dosing based on patient characteristics and surgical 
scenario. This would also be more versatile than pre-produced antibiotic loaded 
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scaffolds and negates issues with antibiotic stability in storage. Soak loading 
microporous scaffolds in antibiotic solution may be a more preferable method to 
achieve more consistent and uniform loading. Further, the dip coating process of 
GelMA has not been optimized as significant drug loss occurred during this rather 
inefficient process. Hence, future experiments will focus on optimising these loading 
and coating methods.  
 
Conclusion: 
3D printed scaffolds with intra-strut microporosity were created by combining 
fused depostion addititive manufacturing and salt-leaching methods for applications in 
tissue engineering. The microporosity allowed for loading and subsequent sustained 
release of Cefazolin using simple solution drop-loading method. The increased surface 
area and the micropores facilitated Cefazolin loading with specific doses and the 
application of GelMA coating reduced the burst release allowing for more sustained 
release compared to scaffolds of solid struts. This type of scaffold design with micro- 
and macro-porosity is promising for several tissue engineering applications where 
loading and local delivery of drugs, nanoparticles or small molecules is desired to 
achieve improved therapy outcome.   
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Highlights 
 
 
 Polycaprolactone scaffolds were manufactured to have dual micro- and macro-
porosity. 
 The microporosity resulted in increased scaffold’s surface area and allowed for 
loading of model drug Cefazolin using drop-loading method. 
 Cefazolin release was enhanced on the microporous scaffolds and sustained for 
up to 3 days. 
 This work demonstrates a new type of scaffolds for potential tissue engineering 
applications where bacterial infection is of concern. 
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